Transition Therapeutics (TTHI) Doses First Patient in TT-401 Phase 1

Transition Therapeutics Inc. (Nasdaq: TTHI) reports that the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug candidate, TT-401. TT-401 is a once-weekly administered peptide being studied for its potential to lower blood glucose levels in patients with type 2 diabetes and accompanying obesity.

Currently approved GLP-1 agonist therapies are a fast growing therapeutic segment emerging as an important approach in the treatment of type 2 diabetes. Next generation therapies for type 2 diabetes are currently being studied in early clinical development for their potential to provide a superior product profile over current GLP-1 product offerings through improved efficacy, broader therapeutic application or less frequent administration. Preclinical data on TT-401 show potential for TT-401 to be administered once-weekly and provide sustained glycemic control and other beneficial effects including weight loss and improvements in lipid profile.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Sigma Lithium resumes full operations after signing TAC agreement
• Elroy Air wins $46M U.S. Army contract for cargo drone system